IRIS
BRUERA, GEMMA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 749
EU - Europa 516
AS - Asia 188
SA - Sud America 3
Totale 1.456
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 744
IE - Irlanda 188
CN - Cina 101
DE - Germania 66
IT - Italia 64
SE - Svezia 62
TR - Turchia 57
UA - Ucraina 38
FR - Francia 26
GB - Regno Unito 23
CZ - Repubblica Ceca 21
FI - Finlandia 17
SG - Singapore 15
VN - Vietnam 10
DM - Dominica 3
IN - India 3
BR - Brasile 2
NL - Olanda 2
PT - Portogallo 2
AT - Austria 1
BN - Brunei Darussalam 1
CA - Canada 1
CL - Cile 1
ES - Italia 1
HU - Ungheria 1
JO - Giordania 1
MD - Moldavia 1
MX - Messico 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
Totale 1.456
Salva come PNG Salva come JPEG
Città #
Chandler 216
Dublin 188
Jacksonville 159
Ashburn 28
Boardman 28
New York 27
Izmir 26
Nanjing 26
Beijing 25
Bremen 25
Lawrence 25
Princeton 25
Wilmington 22
Brno 21
Singapore 12
Nanchang 11
San Mateo 11
Dong Ket 10
Pescara 10
Ann Arbor 8
Hebei 7
L’Aquila 7
Woodbridge 7
Helsinki 6
Milan 6
Munich 6
Kunming 5
Changsha 4
San Francisco 4
Seattle 4
Tianjin 4
Dearborn 3
Des Moines 3
Jiaxing 3
L'aquila 3
Mountain View 3
Redwood City 3
Roseau 3
Shenyang 3
Washington 3
Borås 2
Jinan 2
Monza 2
Norwalk 2
Philadelphia 2
Shanghai 2
Trestina 2
Amman 1
Bandar Seri Begawan 1
Baotou 1
Berlin 1
Boretto 1
Bucharest 1
Budapest 1
Caruaru 1
Changchun 1
Chisinau 1
Dallas 1
Delhi 1
Fremont 1
Fuzhou 1
Guangzhou 1
Houston 1
Kerkrade 1
Lanzhou 1
Madrid 1
Ningbo 1
Poli 1
Pune 1
Shenzhen 1
São Paulo 1
Taizhou 1
Tappahannock 1
Teramo 1
Toronto 1
Verona 1
Vienna 1
Zumpango 1
Totale 1.035
Salva come PNG Salva come JPEG
Nome #
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 99
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 98
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 92
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 81
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 79
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 78
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 69
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer 68
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 68
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 65
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 65
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 63
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 62
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer 60
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 59
Stravaso da antracicline: il punto di vista dell’oncologo. Caso clinico. 56
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A 49
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases 45
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 45
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy 45
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: An experience of multidisciplinary management in clinical practice 44
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. 43
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease 33
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice 33
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments 32
Totale 1.531
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020166 0 2 19 0 0 35 35 9 37 9 0 20
2020/2021197 1 21 4 21 33 8 27 4 26 6 30 16
2021/2022130 5 3 31 7 5 0 0 7 10 0 9 53
2022/2023579 27 42 2 79 55 67 2 32 244 0 12 17
2023/2024135 19 9 9 12 8 38 8 4 0 2 3 23
2024/202545 35 10 0 0 0 0 0 0 0 0 0 0
Totale 1.531